AFR, the ratio of Alb to fibrinogen, combines these two biomarkers and amplifies the sensitivity for evaluating inflammation and nutrition status which has been widely recommended as a prognostic factor in various malignance tumors, such as operable non-small-cell lung cancer and operable soft-tissue sarcoma (36, 37). This evidence concerns the gene ALB and cancer.